ACTR3BP4

Across TCGA pan-cancer cohorts, ACTR3BP4 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated ACTR3BP4 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ACTR3BP4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ACTR3BP4 expression acts as an unfavorable survival marker.

BLCA, STAD, and COAD are the cancer types where ACTR3BP4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	III,IV	0.166	0.586	<.001	66	view →
STAD	DFS	Tertile	IV	0.119	0.476	.002	42	view →
COAD	OS	Tertile	IV	0.039	0.660	<.001	36	view →
UCEC	DFS	Tertile	All	0.810	0.903	.006	36	view →
LIHC	DFS	Tertile	II,III,IV	0.063	0.434	<.001	27	view →
LUSC	DFS	Tertile	III,IV	0.154	0.705	.038	21	view →
PAAD	DFS	Tertile	III,IV	0.118	0.734	.014	18	view →
SARC	OS	Tertile	All	0.681	0.844	.001	18	view →
SKCM	DFS	Tertile	IV	0.036	0.433	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ACTR3BP4–BLCA (OS)

Open the BLCA breakdown →